PhRMA Comments to CMS on Proposed National Coverage Determination for Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

Graphic of a vintage microphone

In recent comments to the administration, PhRMA strongly urged the Centers for Medicare & Medicaid Services to withdraw its proposed National Coverage Determination for Monoclonal Antibodies for the treatment of Alzheimer’s disease.

Graphic of a vintage microphone